DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificates25-08-2022
25-08-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of newspaper publication-Loss of share certificate22-08-2022
Intercept Pharmaceuticals settles Ocaliva patent litigation case with Dr Reddy's
"Under the terms of the agreement, Intercept granted Dr. Reddy's a non-exclusive, non-sublicensable, non-transferable, royalty-free licence to commercialise its generic version of Ocaliva in the United States commencing on October 26, 2035, or earlier under certain circumstances," Intercept Pharmaceuticals in a regulatory filing said.19-08-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Of Related Party Transactions For H2FY22
Disclosure of related party transactions for H2FY2217-08-2022
At least 8 Indian companies working to develop monkeypox vaccine: Report
Among the companies that are working with ICMR are Serum Institute of India (SII), Reliance Life Sciences, Dr Reddy's Laboratories, and Biological E17-08-2022
Pharma@75: More innovation hubs need to come up in the country, says Satish Reddy
Chairman of Dr Reddy's Laboratories says the pandemic has taught us to be resilient15-08-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share certiifcate03-08-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earnings call Transcript Q1 FY2303-08-2022